The US has decided not to increase tariffs on Indian generic medicines, providing relief to drug-makers. However, changes in domestic regulations may make it harder for companies to launch generic versions of new drugs. This move is a response to pressure from the Trump administration to reduce non-tariff barriers for US companies in India.
